Oncosil Medical Ltd has released a press release.
Appendix 4C - Quarterly Cashflow
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from OncoSil Medical
- Oncosils next generation delivery platform
- $10 Million Institutional Placement
- US FDA Investigational Device Exemption submitted
Later from OncoSil Medical
- OncoSil Medical Appoints Global Sales and Marketing Director
- Regulatory Update June 2016
- FDA IDE Approval
- Hot Calibration Run of the OncoSil Device
- Appendix 4E - Preliminary final report 30 June 2016
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical